ArticleFrontiers in immunology2025
TMEM115: a promising marker for glioma immunotherapy and prognosis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioma is a common malignant primary brain tumor characterized by a highly immunosuppressive tumor microenvironment and unfavorable prognosis. Transmembrane protein 115 (TMEM115) is a protein-coding gene. It may play a role in the retrograde transport of proteins from the Golgi to the endoplasmic reticulum. At the same time, it may also play an indirect role in protein glycosylation at the Golgi. However, the role of TMEM115 in glioma progression is still unclear and, therefore, needs further exploration. Methods: RNA-seq data from The Cancer Genome Atlas and Chinese Glioma Genome Atlas databases of glioma patients and multiplex Immunohistochemistry by glioma tissue microarrays were analyzed to determine the expression and localization of TMEM115. Functional assessment of TMEM115 involved cell proliferation, migration, and invasion assays. Pearson's test was utilized to evaluate the association between TMEM115 protein levels, tumor immune infiltrating cells, and immune checkpoints. In addition, χ Results: The results revealed a significant increase in TMEM115 expression in tumors than in non-tumor brain tissues, and knockdown of TMEM115 affects the ability of glioma cell lines to proliferate, migrate, and invade. Additionally, a significant correlation between TMEM115 protein, M2 macrophages (CD68 Conclusion: These findings support TMEM115 as a potential independent prognostic biomarker in glioma and suggest its promise as a target for immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.